



# NATIONAL QUALITY FORUM

Driving measurable health  
improvements together

## Agenda

### Cancer Standing Committee Fall 2019 Measure Evaluation In-Person Meeting

---

February 26, 2020

8:00 am – 5:00 pm ET

National Quality Forum  
1099 14<sup>th</sup> St. NW, Suite 500  
Washington, DC 20005

#### Participant Instructions

For those attending virtually, please follow the instructions below 15 minutes prior to the scheduled start time.

1. Direct your web browser to the following URL:  
<https://core.callinfo.com/callme/?ap=8007682983&ac=9037531&role=p&mode=ad>
2. Enter your name in the fields provided and click “Join Web Meeting”
3. On your phone, please dial **800-768-2983** and use access code **9037531**

#### Meeting Objectives

- Overview of the evaluation process
- Consideration of candidate measures and voting

#### 8:00 am Welcome

*Karen Fields, MD, Co-chair*  
*Shelley Fuld Nasso, MPP, Co-chair*  
*Nicole Williams, MPH, NQF Director*

#### 8:10 am Introductions, Disclosures of Interest, and Cancer Measures Under Review

*Apryl Clark, MHA, NQF Acting Managing Director of Quality Measurement*

#### 8:20 am Overview of Evaluation Process

*Katie Goodwin, MS, NQF Senior Project Manager*

#### 8:30 am Consideration of Candidate Measures

- **1858** Trastuzumab administered to patients with AJCC stage I (T1c) – III and human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy
- **1859** KRAS gene mutation testing performed for patients with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy

#### 10:15 am Break

<http://www.qualityforum.org>

- 10:30 am**      **Consideration of Candidate Measures (continued)**
- **1860** Patients with metastatic colorectal cancer and KRAS gene mutation spared treatment with anti-epidermal growth factor receptor monoclonal antibodies
- 11:30 pm**      **Break for Lunch**
- 12:00 pm**      **Consideration of Candidate Measures (continued)**
- **0384** Oncology-Medical and Radiation-Pain Intensity Quantified (See Fall 2018 review materials)
  - **0384e** Oncology-Medical and Radiation-Pain Intensity Quantified
  - **0383** Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology
- 2:15 pm**      **Break**
- 2:30 pm**      **Consideration of Candidate Measures (continued)**
- **0220** Adjuvant hormonal therapy is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor-positive breast cancer
  - **0219** Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer
  - **0223** Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer
- 4:45 pm**      **NQF Member and Public Comment**  
*Hannah Bui*
- 4:55 pm**      **Next Steps**  
*Hannah Bui*
- 5:00 pm**      **Adjourn**